Long-term monitoring of rec-GH treatment by serial determination of serum aminoterminal propeptide of type III procollagen in children and adults with GH deficiency

Alessandro Sartorio, M. Arosio, A. Conti, S. Ferrero, S. Porretti, G. Faglia

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Serum aminoterminal propeptide of type III procollagen (PIIINP) levels, a reliable marker of collagen formation, were evaluated in children (C = 7) and adults with childhood-onset (CO = 10) and acquired (A = 18) GH deficiency (GHD) before, during and after withdrawal of rec-GH therapy (C = 0.6 IU/kg/week, CO = 0.5 IU/kg/week, A = 0.25 IU/kg/week). The duration of treatment was 12 months for C and A and 6 months for CO; investigations were carried out before and at 3, 6, 9 and 12 months (for C and A) and at 3 and 6 months (for CO) of GH treatment and 6 months after the withdrawal of therapy (for A and CO). Data obtained from patients were compared with those recorded in two age- and sex-matched control groups. Before treatment, serum PIIINP levels were significantly lower (p <0.001) in C with GHD (mean ± SE: 2.9 ± 0.4 ng/ml) than in controls (6.1 ± 0.4 ng/ml), while no significant differences were recorded between adults with CO/A-GHD (3.7 ± 0.5 ng/ml and 3.4 ± 0.2 ng/ml) and controls (3.2 ± 0.2 ng/ml). GH treatment caused a significant increase (p <0.0001) of PIIINP levels both in C (3rd month: 4.4 ± 0.2 ng/ml, 6th month: 5.1 ± 0.4 ng/ml, 12th month: 5.1 ± 0.5 ng/ml), CO-GHD (3rd month: 12.7 ± 1.2 ng/ml; 6th month: 10.2 ± 0.6 ng/ml) and A-GHD (3rd month: 10.0 ± 1.0 ng/ml; 6th month: 8.4 ± 0.6 ng/ml; 12th month: 7.0 ± 0.7 ng/ml), the increase being dose-dependent (more marked and sustained in adults with CO-GHD). The maximal stimulation of collagen synthesis occurred after 3 months of GH treatment in adults with GHD, while a more gradual and less relevant increase was observed in C with GHD. Six months after the withdrawal of GH therapy, serum PIIINP levels of adults with CO-GHD (3.6 ± 0.3 ng/ml) were similar to those recorded before treatment, while in adults with A-GHD serum PIIINP levels (2.6 ± 0.2 ng/ml) were significantly lower (p <0.01) than in basal condition. In conclusion, our study shows that: a) GHD is associated with a reduction of soft tissue formation in children, while it seems to exert no relevant effects in adults with GHD; b) GH therapy causes a rapid stimulation of collagen turnover, which shows a different pattern in children and adults; c) the GH-induced stimulation of collagen synthesis is rapidly removed after the withdrawal of GH treatment. For these reasons, the determination of peripheral markers of GH effects appears useful for the monitoring of GH therapy and can contribute to assess the 'tailored' substitutive dose for the individual patient.

Original languageEnglish
Pages (from-to)169-175
Number of pages7
JournalJournal of Endocrinological Investigation
Volume22
Issue number3
Publication statusPublished - 1999

Fingerprint

Collagen Type III
Carbon Monoxide
Serum
Collagen
Therapeutics
Research Design
procollagen Type III-N-terminal peptide

Keywords

  • Collagen
  • GH
  • GH deficiency

ASJC Scopus subject areas

  • Endocrinology

Cite this

@article{f87139daebe545da829375cd66e444e6,
title = "Long-term monitoring of rec-GH treatment by serial determination of serum aminoterminal propeptide of type III procollagen in children and adults with GH deficiency",
abstract = "Serum aminoterminal propeptide of type III procollagen (PIIINP) levels, a reliable marker of collagen formation, were evaluated in children (C = 7) and adults with childhood-onset (CO = 10) and acquired (A = 18) GH deficiency (GHD) before, during and after withdrawal of rec-GH therapy (C = 0.6 IU/kg/week, CO = 0.5 IU/kg/week, A = 0.25 IU/kg/week). The duration of treatment was 12 months for C and A and 6 months for CO; investigations were carried out before and at 3, 6, 9 and 12 months (for C and A) and at 3 and 6 months (for CO) of GH treatment and 6 months after the withdrawal of therapy (for A and CO). Data obtained from patients were compared with those recorded in two age- and sex-matched control groups. Before treatment, serum PIIINP levels were significantly lower (p <0.001) in C with GHD (mean ± SE: 2.9 ± 0.4 ng/ml) than in controls (6.1 ± 0.4 ng/ml), while no significant differences were recorded between adults with CO/A-GHD (3.7 ± 0.5 ng/ml and 3.4 ± 0.2 ng/ml) and controls (3.2 ± 0.2 ng/ml). GH treatment caused a significant increase (p <0.0001) of PIIINP levels both in C (3rd month: 4.4 ± 0.2 ng/ml, 6th month: 5.1 ± 0.4 ng/ml, 12th month: 5.1 ± 0.5 ng/ml), CO-GHD (3rd month: 12.7 ± 1.2 ng/ml; 6th month: 10.2 ± 0.6 ng/ml) and A-GHD (3rd month: 10.0 ± 1.0 ng/ml; 6th month: 8.4 ± 0.6 ng/ml; 12th month: 7.0 ± 0.7 ng/ml), the increase being dose-dependent (more marked and sustained in adults with CO-GHD). The maximal stimulation of collagen synthesis occurred after 3 months of GH treatment in adults with GHD, while a more gradual and less relevant increase was observed in C with GHD. Six months after the withdrawal of GH therapy, serum PIIINP levels of adults with CO-GHD (3.6 ± 0.3 ng/ml) were similar to those recorded before treatment, while in adults with A-GHD serum PIIINP levels (2.6 ± 0.2 ng/ml) were significantly lower (p <0.01) than in basal condition. In conclusion, our study shows that: a) GHD is associated with a reduction of soft tissue formation in children, while it seems to exert no relevant effects in adults with GHD; b) GH therapy causes a rapid stimulation of collagen turnover, which shows a different pattern in children and adults; c) the GH-induced stimulation of collagen synthesis is rapidly removed after the withdrawal of GH treatment. For these reasons, the determination of peripheral markers of GH effects appears useful for the monitoring of GH therapy and can contribute to assess the 'tailored' substitutive dose for the individual patient.",
keywords = "Collagen, GH, GH deficiency",
author = "Alessandro Sartorio and M. Arosio and A. Conti and S. Ferrero and S. Porretti and G. Faglia",
year = "1999",
language = "English",
volume = "22",
pages = "169--175",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "3",

}

TY - JOUR

T1 - Long-term monitoring of rec-GH treatment by serial determination of serum aminoterminal propeptide of type III procollagen in children and adults with GH deficiency

AU - Sartorio, Alessandro

AU - Arosio, M.

AU - Conti, A.

AU - Ferrero, S.

AU - Porretti, S.

AU - Faglia, G.

PY - 1999

Y1 - 1999

N2 - Serum aminoterminal propeptide of type III procollagen (PIIINP) levels, a reliable marker of collagen formation, were evaluated in children (C = 7) and adults with childhood-onset (CO = 10) and acquired (A = 18) GH deficiency (GHD) before, during and after withdrawal of rec-GH therapy (C = 0.6 IU/kg/week, CO = 0.5 IU/kg/week, A = 0.25 IU/kg/week). The duration of treatment was 12 months for C and A and 6 months for CO; investigations were carried out before and at 3, 6, 9 and 12 months (for C and A) and at 3 and 6 months (for CO) of GH treatment and 6 months after the withdrawal of therapy (for A and CO). Data obtained from patients were compared with those recorded in two age- and sex-matched control groups. Before treatment, serum PIIINP levels were significantly lower (p <0.001) in C with GHD (mean ± SE: 2.9 ± 0.4 ng/ml) than in controls (6.1 ± 0.4 ng/ml), while no significant differences were recorded between adults with CO/A-GHD (3.7 ± 0.5 ng/ml and 3.4 ± 0.2 ng/ml) and controls (3.2 ± 0.2 ng/ml). GH treatment caused a significant increase (p <0.0001) of PIIINP levels both in C (3rd month: 4.4 ± 0.2 ng/ml, 6th month: 5.1 ± 0.4 ng/ml, 12th month: 5.1 ± 0.5 ng/ml), CO-GHD (3rd month: 12.7 ± 1.2 ng/ml; 6th month: 10.2 ± 0.6 ng/ml) and A-GHD (3rd month: 10.0 ± 1.0 ng/ml; 6th month: 8.4 ± 0.6 ng/ml; 12th month: 7.0 ± 0.7 ng/ml), the increase being dose-dependent (more marked and sustained in adults with CO-GHD). The maximal stimulation of collagen synthesis occurred after 3 months of GH treatment in adults with GHD, while a more gradual and less relevant increase was observed in C with GHD. Six months after the withdrawal of GH therapy, serum PIIINP levels of adults with CO-GHD (3.6 ± 0.3 ng/ml) were similar to those recorded before treatment, while in adults with A-GHD serum PIIINP levels (2.6 ± 0.2 ng/ml) were significantly lower (p <0.01) than in basal condition. In conclusion, our study shows that: a) GHD is associated with a reduction of soft tissue formation in children, while it seems to exert no relevant effects in adults with GHD; b) GH therapy causes a rapid stimulation of collagen turnover, which shows a different pattern in children and adults; c) the GH-induced stimulation of collagen synthesis is rapidly removed after the withdrawal of GH treatment. For these reasons, the determination of peripheral markers of GH effects appears useful for the monitoring of GH therapy and can contribute to assess the 'tailored' substitutive dose for the individual patient.

AB - Serum aminoterminal propeptide of type III procollagen (PIIINP) levels, a reliable marker of collagen formation, were evaluated in children (C = 7) and adults with childhood-onset (CO = 10) and acquired (A = 18) GH deficiency (GHD) before, during and after withdrawal of rec-GH therapy (C = 0.6 IU/kg/week, CO = 0.5 IU/kg/week, A = 0.25 IU/kg/week). The duration of treatment was 12 months for C and A and 6 months for CO; investigations were carried out before and at 3, 6, 9 and 12 months (for C and A) and at 3 and 6 months (for CO) of GH treatment and 6 months after the withdrawal of therapy (for A and CO). Data obtained from patients were compared with those recorded in two age- and sex-matched control groups. Before treatment, serum PIIINP levels were significantly lower (p <0.001) in C with GHD (mean ± SE: 2.9 ± 0.4 ng/ml) than in controls (6.1 ± 0.4 ng/ml), while no significant differences were recorded between adults with CO/A-GHD (3.7 ± 0.5 ng/ml and 3.4 ± 0.2 ng/ml) and controls (3.2 ± 0.2 ng/ml). GH treatment caused a significant increase (p <0.0001) of PIIINP levels both in C (3rd month: 4.4 ± 0.2 ng/ml, 6th month: 5.1 ± 0.4 ng/ml, 12th month: 5.1 ± 0.5 ng/ml), CO-GHD (3rd month: 12.7 ± 1.2 ng/ml; 6th month: 10.2 ± 0.6 ng/ml) and A-GHD (3rd month: 10.0 ± 1.0 ng/ml; 6th month: 8.4 ± 0.6 ng/ml; 12th month: 7.0 ± 0.7 ng/ml), the increase being dose-dependent (more marked and sustained in adults with CO-GHD). The maximal stimulation of collagen synthesis occurred after 3 months of GH treatment in adults with GHD, while a more gradual and less relevant increase was observed in C with GHD. Six months after the withdrawal of GH therapy, serum PIIINP levels of adults with CO-GHD (3.6 ± 0.3 ng/ml) were similar to those recorded before treatment, while in adults with A-GHD serum PIIINP levels (2.6 ± 0.2 ng/ml) were significantly lower (p <0.01) than in basal condition. In conclusion, our study shows that: a) GHD is associated with a reduction of soft tissue formation in children, while it seems to exert no relevant effects in adults with GHD; b) GH therapy causes a rapid stimulation of collagen turnover, which shows a different pattern in children and adults; c) the GH-induced stimulation of collagen synthesis is rapidly removed after the withdrawal of GH treatment. For these reasons, the determination of peripheral markers of GH effects appears useful for the monitoring of GH therapy and can contribute to assess the 'tailored' substitutive dose for the individual patient.

KW - Collagen

KW - GH

KW - GH deficiency

UR - http://www.scopus.com/inward/record.url?scp=0032924002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032924002&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 169

EP - 175

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 3

ER -